# [Links to HHS Strategic Goals]{.smallcaps}

The table below presents the NIH GPRA Goals in support of the HHS
Strategic Goals.

+-----------------------------------------+---+---+----+---+---+---+---+---+
| NIH GPRA Goals                          | * |   |    |   |   |   |   |   |
|                                         | * |   |    |   |   |   |   |   |
|                                         | H |   |    |   |   |   |   |   |
|                                         | H |   |    |   |   |   |   |   |
|                                         | S |   |    |   |   |   |   |   |
|                                         | S |   |    |   |   |   |   |   |
|                                         | t |   |    |   |   |   |   |   |
|                                         | r |   |    |   |   |   |   |   |
|                                         | a |   |    |   |   |   |   |   |
|                                         | t |   |    |   |   |   |   |   |
|                                         | e |   |    |   |   |   |   |   |
|                                         | g |   |    |   |   |   |   |   |
|                                         | i |   |    |   |   |   |   |   |
|                                         | c |   |    |   |   |   |   |   |
|                                         | G |   |    |   |   |   |   |   |
|                                         | o |   |    |   |   |   |   |   |
|                                         | a |   |    |   |   |   |   |   |
|                                         | l |   |    |   |   |   |   |   |
|                                         | s |   |    |   |   |   |   |   |
|                                         | * |   |    |   |   |   |   |   |
|                                         | * |   |    |   |   |   |   |   |
+=========================================+===+===+====+===+===+===+===+===+
|                                         | > | > | >  | > | > | > | > | > |
|                                         |   |   | Go |   |   |   |   |   |
|                                         | G | G | al | G | G | G | G | G |
|                                         | o | o | >  | o | o | o | o | o |
|                                         | a | a | 3: | a | a | a | a | a |
|                                         | l | l | >  | l | l | l | l | l |
|                                         | > | > | In | > | > | > | > | > |
|                                         |   |   | cr |   |   |   |   |   |
|                                         | 1 | 2 | ea | 4 | 5 | 6 | 7 | 8 |
|                                         | : | : | se | : | : | : | : | : |
|                                         | > | > | >  | > | > | > | > | > |
|                                         |   |   |  t |   |   |   |   |   |
|                                         | R | E | he | E | I | I | I | A |
|                                         | e | n | >  | n | m | m | m | c |
|                                         | d | h | pe | h | p | p | p | h |
|                                         | u | a | rc | a | r | r | r | i |
|                                         | c | n | en | n | o | o | o | e |
|                                         | e | c | ta | c | v | v | v | v |
|                                         | > | e | ge | e | e | e | e | e |
|                                         |   | > | >  | > | > | > | > | > |
|                                         | t |   | of |   |   |   |   |   |
|                                         | h | t | >  | t | t | t | t | e |
|                                         | e | h |  t | h | h | h | h | x |
|                                         | > | e | he | e | e | e | e | c |
|                                         |   | > | >  | > | > | > | > | e |
|                                         | m |   | Na |   |   |   |   | l |
|                                         | a | a | ti | c | q | e | s | l |
|                                         | j | b | on | a | u | c | t | e |
|                                         | o | i | 's | p | a | o | a | n |
|                                         | r | l | >  | a | l | n | b | c |
|                                         | > | i | ch | c | i | o | i | e |
|                                         |   | t | il | i | t | m | l | > |
|                                         | t | y | dr | t | y | i | i |   |
|                                         | h | > | en | y | > | c | t | i |
|                                         | r |   | >  | > |   | > | y | n |
|                                         | e | o |  a |   | o |   | > | > |
|                                         | a | f | nd | a | f | a |   |   |
|                                         | t | > | >  | n | > | n | a | m |
|                                         | s |   | ad | d |   | d | n | a |
|                                         | > | t | ul | > | h | > | d | n |
|                                         |   | h | ts |   | e |   | > | a |
|                                         | t | e | >  | p | a | s |   | g |
|                                         | o | > |  w | r | l | o | h | e |
|                                         | > |   | ho | o | t | c | e | m |
|                                         |   | N | >  | d | h | i | a | e |
|                                         | t | a | ha | u | > | a | l | n |
|                                         | h | t | ve | c |   | l | t | t |
|                                         | e | i | >  | t | c | > | h | > |
|                                         | > | o | ac | i | a |   | y |   |
|                                         |   | n | ce | v | r | w | > | p |
|                                         | h | ' | ss | i | e | e |   | r |
|                                         | e | s | >  | t | > | l | d | a |
|                                         | a | > | to | y |   | l | e | c |
|                                         | l |   | >  | > | s | - | v | t |
|                                         | t | h | he |   | e | b | e | i |
|                                         | h | e | al | o | r | e | l | c |
|                                         | > | a | th | f | v | i | o | e |
|                                         |   | l | >  | > | i | n | p | s |
|                                         | a | t | ca |   | c | g | m |   |
|                                         | n | h | re | t | e | > | e |   |
|                                         | d | > | >  | h | s |   | n |   |
|                                         | > |   |  s | e |   | o | t |   |
|                                         |   | c | er | > |   | f | > |   |
|                                         | w | a | vi |   |   | > |   |   |
|                                         | e | r | ce | N |   |   | o |   |
|                                         | l | e | s, | a |   | i | f |   |
|                                         | l | > | >  | t |   | n | > |   |
|                                         | - |   |  a | i |   | d |   |   |
|                                         | b | s | nd | o |   | i | o |   |
|                                         | e | y | >  | n |   | v | u |   |
|                                         | i | s | ex | ' |   | i | r |   |
|                                         | n | t | pa | s |   | d | > |   |
|                                         | g | e | nd | > |   | u |   |   |
|                                         | > | m | >  |   |   | a | N |   |
|                                         |   | > | co | h |   | l | a |   |
|                                         | o |   | ns | e |   | s | t |   |
|                                         | f | t | um | a |   | , | i |   |
|                                         | > | o | er | l |   | > | o |   |
|                                         |   | > | >  | t |   |   | n |   |
|                                         | A |   |  c | h |   | f | ' |   |
|                                         | m | e | ho | > |   | a | s |   |
|                                         | e | f | ic |   |   | m | > |   |
|                                         | r | f | es | s |   | i |   |   |
|                                         | i | e |    | c |   | l | c |   |
|                                         | c | c |    | i |   | i | h |   |
|                                         | a | t |    | e |   | e | i |   |
|                                         |   | i |    | n |   | s | l |   |
|                                         |   | v |    | c |   | , | d |   |
|                                         |   | e |    | e |   | > | r |   |
|                                         |   | l |    | > |   |   | e |   |
|                                         |   | y |    |   |   | a | n |   |
|                                         |   | > |    | r |   | n | > |   |
|                                         |   |   |    | e |   | d |   |   |
|                                         |   | r |    | s |   | > | a |   |
|                                         |   | e |    | e |   |   | n |   |
|                                         |   | s |    | a |   | c | d |   |
|                                         |   | p |    | r |   | o | > |   |
|                                         |   | o |    | c |   | m |   |   |
|                                         |   | n |    | h |   | m | y |   |
|                                         |   | d |    | > |   | u | o |   |
|                                         |   | > |    |   |   | n | u |   |
|                                         |   |   |    | e |   | i | t |   |
|                                         |   | t |    | n |   | t | h |   |
|                                         |   | o |    | t |   | i |   |   |
|                                         |   | > |    | e |   | e |   |   |
|                                         |   |   |    | r |   | s |   |   |
|                                         |   | b |    | p |   | , |   |   |
|                                         |   | i |    | r |   | > |   |   |
|                                         |   | o |    | i |   |   |   |   |
|                                         |   | t |    | s |   | e |   |   |
|                                         |   | e |    | e |   | s |   |   |
|                                         |   | r |    |   |   | p |   |   |
|                                         |   | r |    |   |   | e |   |   |
|                                         |   | o |    |   |   | c |   |   |
|                                         |   | r |    |   |   | i |   |   |
|                                         |   | i |    |   |   | a |   |   |
|                                         |   | s |    |   |   | l |   |   |
|                                         |   | m |    |   |   | l |   |   |
|                                         |   | > |    |   |   | y |   |   |
|                                         |   |   |    |   |   | > |   |   |
|                                         |   | a |    |   |   |   |   |   |
|                                         |   | n |    |   |   | t |   |   |
|                                         |   | d |    |   |   | h |   |   |
|                                         |   | > |    |   |   | o |   |   |
|                                         |   |   |    |   |   | s |   |   |
|                                         |   | o |    |   |   | e |   |   |
|                                         |   | t |    |   |   | > |   |   |
|                                         |   | h |    |   |   |   |   |   |
|                                         |   | e |    |   |   | m |   |   |
|                                         |   | r |    |   |   | o |   |   |
|                                         |   | > |    |   |   | s |   |   |
|                                         |   |   |    |   |   | t |   |   |
|                                         |   | p |    |   |   | > |   |   |
|                                         |   | u |    |   |   |   |   |   |
|                                         |   | b |    |   |   | i |   |   |
|                                         |   | l |    |   |   | n |   |   |
|                                         |   | i |    |   |   | > |   |   |
|                                         |   | c |    |   |   |   |   |   |
|                                         |   | > |    |   |   | n |   |   |
|                                         |   |   |    |   |   | e |   |   |
|                                         |   | h |    |   |   | e |   |   |
|                                         |   | e |    |   |   | d |   |   |
|                                         |   | a |    |   |   |   |   |   |
|                                         |   | l |    |   |   |   |   |   |
|                                         |   | t |    |   |   |   |   |   |
|                                         |   | h |    |   |   |   |   |   |
|                                         |   | > |    |   |   |   |   |   |
|                                         |   |   |    |   |   |   |   |   |
|                                         |   | c |    |   |   |   |   |   |
|                                         |   | h |    |   |   |   |   |   |
|                                         |   | a |    |   |   |   |   |   |
|                                         |   | l |    |   |   |   |   |   |
|                                         |   | l |    |   |   |   |   |   |
|                                         |   | e |    |   |   |   |   |   |
|                                         |   | n |    |   |   |   |   |   |
|                                         |   | g |    |   |   |   |   |   |
|                                         |   | e |    |   |   |   |   |   |
|                                         |   | s |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| > **Scientific Research Outcomes        |   |   |    |   |   |   |   |   |
| > (SRO)**                               |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| SRO-1.1: By 2007, conduct medications   | X |   |    | X |   |   |   |   |
| development using animal models and     |   |   |    |   |   |   |   |   |
| begin conducting Phase I and II human   |   |   |    |   |   |   |   |   |
| trials of two potential treatments for  |   |   |    |   |   |   |   |   |
| alcoholism: the cannabinoid antagonist  |   |   |    |   |   |   |   |   |
| rimonabant and the                      |   |   |    |   |   |   |   |   |
| corticotropin-releasing hormone         |   |   |    |   |   |   |   |   |
| antagonist antalarmin.                  |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| SRO-1.2: By 2006, develop one or more   |   |   |    | X |   | X |   |   |
| prototypes for a low-power, highly      |   |   |    |   |   |   |   |   |
| directional hearing aid microphone to   |   |   |    |   |   |   |   |   |
| help hearing-impaired persons better    |   |   |    |   |   |   |   |   |
| understand speech in a noisy            |   |   |    |   |   |   |   |   |
| background.                             |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| SRO-1.2.3: By 2006, develop methods     |   |   |    | X |   |   |   |   |
| that can classify at least 75% of       |   |   |    |   |   |   |   |   |
| proteins from sequenced genomes         |   |   |    |   |   |   |   |   |
| according to evolutionary origin and    |   |   |    |   |   |   |   |   |
| biological structure.                   |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| SRO-2.2: By 2009, evaluate the efficacy | X |   |    | X |   |   |   |   |
| of two novel approaches to prevent      |   |   |    |   |   |   |   |   |
| weight gain and/or treat obesity in     |   |   |    |   |   |   |   |   |
| clinical trials in humans.              |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| SRO-2.4: By 2009, the Laboratory of     |   |   |    | X |   |   |   |   |
| Symptom Management will develop and     |   |   |    |   |   |   |   |   |
| test multidisciplinary biobehavioral    |   |   |    |   |   |   |   |   |
| interventions to prevent/attenuate      |   |   |    |   |   |   |   |   |
| disease- and treatment-related symptoms |   |   |    |   |   |   |   |   |
| such as pain, fatigue, and              |   |   |    |   |   |   |   |   |
| psychological distress, to reduce       |   |   |    |   |   |   |   |   |
| related symptom burden and to increase  |   |   |    |   |   |   |   |   |
| functional status and quality of life.  |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| SRO-2.3.2: By 2010, develop one         |   | X |    | X |   |   |   |   |
| universal antibiotic effective against  |   |   |    |   |   |   |   |   |
| multiple classes of biological          |   |   |    |   |   |   |   |   |
| pathogens.                              |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| SRO-2.3.4: By 2010, develop an HIV/AIDS | X |   |    | X |   |   |   |   |
| vaccine.                                |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| SRO-3.1: By 2013, identify at least one |   |   |    | X |   | X |   |   |
| clinical intervention that will delay   |   |   |    |   |   |   |   |   |
| the progression, delay the onset, or    |   |   |    |   |   |   |   |   |
| prevent Alzheimer's disease (AD).       |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| SRO-3.2.1: By 2015, evaluate islet      |   |   |    | X |   |   |   |   |
| transplantation in combination with     |   |   |    |   |   |   |   |   |
| immune modulation strategies for the    |   |   |    |   |   |   |   |   |
| treatment of type 1 diabetes in         |   |   |    |   |   |   |   |   |
| clinical trials.                        |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| SRO-3.3: By 2013, determine the         |   |   |    | X |   |   |   |   |
| efficacy of using salivary diagnostics  |   |   |    |   |   |   |   |   |
| to monitor health and diagnose at least |   |   |    |   |   |   |   |   |
| one systemic disease.                   |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| SRO-3.5: By 2013, identify and          | X |   |    | X |   |   |   |   |
| characterize at least 2 human candidate |   |   |    |   |   |   |   |   |
| genes that mutually influence risk for  |   |   |    |   |   |   |   |   |
| substance use disorders and risk for    |   |   |    |   |   |   |   |   |
| comorbid psychiatric disorders using    |   |   |    |   |   |   |   |   |
| high-risk family, twin, and special     |   |   |    |   |   |   |   |   |
| population studies.                     |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| SRO-3.6: By 2012, develop and apply     |   |   |    | X |   |   |   |   |
| clinically one new imaging technique to |   |   |    |   |   |   |   |   |
| enable tracking the mobility of stem    |   |   |    |   |   |   |   |   |
| cells within cardiovascular tissues.    |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| SRO-4.5.1: By 2007, evaluate the        |   |   |    | X |   |   |   |   |
| efficacy of three new treatment         |   |   |    |   |   |   |   |   |
| strategies for HIV infection in         |   |   |    |   |   |   |   |   |
| clinical trials in an effort to         |   |   |    |   |   |   |   |   |
| identify agents or combinations of      |   |   |    |   |   |   |   |   |
| agents that are more effective, less    |   |   |    |   |   |   |   |   |
| toxic, and/or simpler to use than       |   |   |    |   |   |   |   |   |
| current recommended HIV treatment       |   |   |    |   |   |   |   |   |
| regimens.                               |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| SRO-4.5.4: By 2007, identify 20 small   |   |   |    | X |   |   |   |   |
| molecules that are active in models of  |   |   |    |   |   |   |   |   |
| nervous system function or disease and  |   |   |    |   |   |   |   |   |
| show promise as drugs, diagnostic       |   |   |    |   |   |   |   |   |
| agents, or research tools.              |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| SRO-4.5.5: By 2008, develop and test    | X |   | X  |   |   |   |   |   |
| new evidence-based treatment approaches |   |   |    |   |   |   |   |   |
| for drug abuse in community settings.   |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| SRO-5.2: By 2009, determine the         |   |   |    | X |   |   |   |   |
| efficacy of statins in preventing the   |   |   |    |   |   |   |   |   |
| progression of atherosclerosis in       |   |   |    |   |   |   |   |   |
| children with systemic lupus            |   |   |    |   |   |   |   |   |
| erythematosus (SLE, or lupus).          |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| SRO-5.3: By 2009, expand the range of   |   |   |    | X |   |   |   |   |
| available methods used to create,       |   |   |    |   |   |   |   |   |
| analyze, and utilize chemical           |   |   |    |   |   |   |   |   |
| libraries, which can be used to         |   |   |    |   |   |   |   |   |
| discover new medications. Specifically, |   |   |    |   |   |   |   |   |
| use these chemical libraries to         |   |   |    |   |   |   |   |   |
| discover 10 new and unique chemical     |   |   |    |   |   |   |   |   |
| structures that could serve as the      |   |   |    |   |   |   |   |   |
| starting point for new drugs.           |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| SRO-5.6: By 2009, identify 1 or 2 new   | X |   |    | X |   |   |   |   |
| medication candidates to further test   |   |   |    |   |   |   |   |   |
| and develop for the treatment of        |   |   |    |   |   |   |   |   |
| tobacco addiction.                      |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| SRO-5.6.2: By 2011, assess the efficacy | X |   |    | X |   |   |   |   |
| of at least three new treatment         |   |   |    |   |   |   |   |   |
| strategies to reduce cardiovascular     |   |   |    |   |   |   |   |   |
| morbidity/mortality in patients with    |   |   |    |   |   |   |   |   |
| type 2 diabetes and/or chronic kidney   |   |   |    |   |   |   |   |   |
| disease.                                |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| SRO-5.7: By 2010, validate and compare  |   |   |    | X |   |   |   |   |
| 4 imaging methods of assessing lung     |   |   |    |   |   |   |   |   |
| cancer response to therapy.             |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| SRO-5.8: By 2010, improve device(s) to  |   |   |    | X |   |   |   |   |
| measure hot flashes and test device(s)  |   |   |    |   |   |   |   |   |
| in clinical trials.                     |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| SRO-5.9: By 2010, establish the role of |   |   | X  |   |   |   |   |   |
| genetic factors in three major diseases |   |   |    |   |   |   |   |   |
| for which health disparities are noted  |   |   |    |   |   |   |   |   |
| between populations.                    |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| SRO-6.1: By 2012, identify the genes    |   |   |    | X |   | X |   |   |
| that control the risk of development of |   |   |    |   |   |   |   |   |
| age-related macular degeneration (AMD)  |   |   |    |   |   |   |   |   |
| and glaucoma in humans.                 |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| SRO-6.3: By 2008, develop a knowledge   |   |   |    | X |   |   |   |   |
| base on chemical effects in biological  |   |   |    |   |   |   |   |   |
| systems using a systems toxicology or   |   |   |    |   |   |   |   |   |
| toxicogenomics approach.                |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| SRO-6.4: By 2014, identify and          |   |   |    | X |   |   |   |   |
| characterize two molecular pathways of  |   |   |    |   |   |   |   |   |
| potential clinical significance to      |   |   |    |   |   |   |   |   |
| serve as the basis for discovering new  |   |   |    |   |   |   |   |   |
| medications for preventing and treating |   |   |    |   |   |   |   |   |
| asthma exacerbations.                   |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| SRO-7.2: By 2006, integrate             |   |   |    | X |   |   |   |   |
| nanotechnology-based components into a  |   |   |    |   |   |   |   |   |
| system capable of detecting specific    |   |   |    |   |   |   |   |   |
| biomarkers (molecular signatures) to    |   |   |    |   |   |   |   |   |
| establish proof of concept for a new    |   |   |    |   |   |   |   |   |
| approach to the early detection of      |   |   |    |   |   |   |   |   |
| cancer and, ultimately, cancer          |   |   |    |   |   |   |   |   |
| preemption.                             |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| SRO-7.8.1: By 2007, determine the       | X | X |    | X |   |   |   |   |
| genome sequences of an additional 45    |   |   |    |   |   |   |   |   |
| human pathogens and 3 invertebrate      |   |   |    |   |   |   |   |   |
| vectors of infectious diseases.         |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| SRO-7.8.3: By 2006, build a publicly    |   |   |    | X |   |   |   |   |
| accessible Collection of Reference      |   |   |    |   |   |   |   |   |
| Sequences (RefSeq Collection) to serve  |   |   |    |   |   |   |   |   |
| as the basis for medical, functional,   |   |   |    |   |   |   |   |   |
| and diversity studies. A comprehensive  |   |   |    |   |   |   |   |   |
| RefSeq Collection will serve as a       |   |   |    |   |   |   |   |   |
| foundation for genomic research by      |   |   |    |   |   |   |   |   |
| providing a centralized, integrated,    |   |   |    |   |   |   |   |   |
| nonredundant set of sequences,          |   |   |    |   |   |   |   |   |
| including genomic deoxyribonucleic acid |   |   |    |   |   |   |   |   |
| (DNA), ribonucleic acid (RNA)           |   |   |    |   |   |   |   |   |
| transcript, and proteome (protein       |   |   |    |   |   |   |   |   |
| product) sequences, integrated with     |   |   |    |   |   |   |   |   |
| other vital information for all major   |   |   |    |   |   |   |   |   |
| research organisms.                     |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| SRO-8.2: By 2009, identify and          |   |   |    | X |   | X |   |   |
| characterize two molecular interactions |   |   |    |   |   |   |   |   |
| of potential clinical significance      |   |   |    |   |   |   |   |   |
| between bone-forming cells and          |   |   |    |   |   |   |   |   |
| components of bone. Such interactions   |   |   |    |   |   |   |   |   |
| are defined as those having significant |   |   |    |   |   |   |   |   |
| impact on the accrual of bone mass or   |   |   |    |   |   |   |   |   |
| the actual mechanical performance of    |   |   |    |   |   |   |   |   |
| bone (i.e., fracture resistance) in     |   |   |    |   |   |   |   |   |
| laboratory animals.                     |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| SRO-8.4: By 2009, assess the impact of  |   |   |    | X |   |   |   |   |
| two major Institutional Development     |   |   |    |   |   |   |   |   |
| Award (IDeA) Programs on the            |   |   |    |   |   |   |   |   |
| development of competitive              |   |   |    |   |   |   |   |   |
| investigators and their capacities to   |   |   |    |   |   |   |   |   |
| compete for NIH research funding.       |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| SRO-8.5: By 2009, develop an item bank  |   |   |    | X |   |   |   |   |
| and computerized adaptive testing       |   |   |    |   |   |   |   |   |
| system available to clinical            |   |   |    |   |   |   |   |   |
| researchers to improve assessment of    |   |   |    |   |   |   |   |   |
| non-specific symptoms (e.g., pain and   |   |   |    |   |   |   |   |   |
| fatigue) and other domains of           |   |   |    |   |   |   |   |   |
| health-related quality of life in       |   |   |    |   |   |   |   |   |
| chronic disease.                        |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| SRO-8.6: By 2011, develop stable        |   |   |    | X |   |   |   |   |
| national estimates of vision impairment |   |   |    |   |   |   |   |   |
| by extending the vision component of    |   |   |    |   |   |   |   |   |
| the National Health and Nutrition       |   |   |    |   |   |   |   |   |
| Examination Survey (NHANES).            |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| SRO-8.9.1: By 2010, demonstrate through |   |   |    | X |   | X |   |   |
| research a capacity to reduce the total |   |   |    |   |   |   |   |   |
| years lost to disability (YLDs) in the  |   |   |    |   |   |   |   |   |
| United States by 10% by (1) developing  |   |   |    |   |   |   |   |   |
| treatment algorithms to improve the     |   |   |    |   |   |   |   |   |
| management of treatment-resistant and   |   |   |    |   |   |   |   |   |
| recurrent depression and (2)            |   |   |    |   |   |   |   |   |
| elucidating the mechanisms by which     |   |   |    |   |   |   |   |   |
| depression influences at least two      |   |   |    |   |   |   |   |   |
| comorbid physical illnesses (e.g.,      |   |   |    |   |   |   |   |   |
| heart disease, cancer, Parkinson's      |   |   |    |   |   |   |   |   |
| disease, or diabetes).                  |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| SRO-8.9.2: By 2010, identify culturally | X |   | X  | X |   |   |   |   |
| appropriate, effective stroke           |   |   |    |   |   |   |   |   |
| prevention programs for nationwide      |   |   |    |   |   |   |   |   |
| implementation in minority communities. |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| SRO-8.9.3: By 2012, create a database   |   |   |    | X |   |   | X |   |
| and analytical software that            |   |   |    |   |   |   |   |   |
| illustrates the progression of normal   |   |   |    |   |   |   |   |   |
| MRI measurement of brain development in |   |   |    |   |   |   |   |   |
| a nationally representative sample of   |   |   |    |   |   |   |   |   |
| children in the United States.          |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| *SRO-9.4: By 2013, develop and evaluate |   |   |    | X |   |   | X |   |
| the efficacy of neonatal screening for  |   |   |    |   |   |   |   |   |
| congenital cytomegalovirus (CMV)        |   |   |    |   |   |   |   |   |
| infection to permit identification of   |   |   |    |   |   |   |   |   |
| infants who will develop CMV-induced    |   |   |    |   |   |   |   |   |
| hearing loss in the first years of      |   |   |    |   |   |   |   |   |
| life.*                                  |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| **Communication and Transfer of Results |   |   |    |   |   |   |   |   |
| (CTR)**                                 |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| CTR-1: By 2008, reduce the disparity    |   |   | X  | X |   |   | X |   |
| between African American and white      |   |   |    |   |   |   |   |   |
| infants in back sleeping by 50% to      |   |   |    |   |   |   |   |   |
| further reduce the risk of sudden       |   |   |    |   |   |   |   |   |
| infant death syndrome (SIDS).           |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| CTR-2: By 2006, increase awareness      | X |   |    | X |   |   |   |   |
| among the general public about the      |   |   |    |   |   |   |   |   |
| symptoms of stroke and the need to seek |   |   |    |   |   |   |   |   |
| treatment rapidly by partnering with    |   |   |    |   |   |   |   |   |
| providers and volunteers in at least    |   |   |    |   |   |   |   |   |
| five communities and extending the      |   |   |    |   |   |   |   |   |
| impact of the National Institute of     |   |   |    |   |   |   |   |   |
| Neurological Disorders and Stroke       |   |   |    |   |   |   |   |   |
| campaign "Know Stroke. Know the Signs.  |   |   |    |   |   |   |   |   |
| Act in Time."                           |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| CTR-3: By 2006, through education and   |   |   |    | X |   |   |   |   |
| technical assistance, strengthen the    |   |   |    |   |   |   |   |   |
| capacity of developing countries to     |   |   |    |   |   |   |   |   |
| identify technologies and pursue their  |   |   |    |   |   |   |   |   |
| development into products.              |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| CTR-4: By 2008, increase the percentage |   |   |    | X |   |   |   |   |
| of Small Business Innovation Research   |   |   |    |   |   |   |   |   |
| (SBIR) Program award recipients who are |   |   |    |   |   |   |   |   |
| successful in identifying the resources |   |   |    |   |   |   |   |   |
| and/or partners necessary to further    |   |   |    |   |   |   |   |   |
| the development of their SBIR projects  |   |   |    |   |   |   |   |   |
| toward commercialization.               |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| CTR-5: By 2013, improve marketing and   |   |   |    | X |   |   |   | X |
| management of NIH intellectual property |   |   |    |   |   |   |   |   |
| (IP) assets by building data mining     |   |   |    |   |   |   |   |   |
| capability.                             |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| **Capacity Building and Research        |   |   |    |   |   |   |   |   |
| Resources (CBRR)**                      |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| CBRR-1: By 2012, recruit, train, and    |   |   |    | X |   |   |   |   |
| retain a diverse population of highly   |   |   |    |   |   |   |   |   |
| trained scientists in biomedical,       |   |   |    |   |   |   |   |   |
| behavioral, and clinical research using |   |   |    |   |   |   |   |   |
| research training grants, fellowships,  |   |   |    |   |   |   |   |   |
| career development awards, and student  |   |   |    |   |   |   |   |   |
| loan repayment programs.                |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| CBRR-2: Promote data sharing and        |   |   |    |   |   |   |   | X |
| provide information in real time by     |   |   |    |   |   |   |   |   |
| implementing the NIH Business System.   |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| CBRR-3: By 2007, streamline business    |   |   |    |   | X |   |   | X |
| processes and automate data movement by |   |   |    |   |   |   |   |   |
| implementing the Clinical Research      |   |   |    |   |   |   |   |   |
| Information System (CRIS).              |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| CBRR-4: By 2013, provide greater        |   |   |    |   |   |   |   | X |
| functionality and more streamlined      |   |   |    |   |   |   |   |   |
| processes in grants administration by   |   |   |    |   |   |   |   |   |
| continuing to develop the NIH           |   |   |    |   |   |   |   |   |
| electronic research administration      |   |   |    |   |   |   |   |   |
| (eRA).                                  |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| CBRR-5: By 2006, expand by 50% the pool |   |   |    | X |   |   |   |   |
| of researchers trained in biomedical    |   |   |    |   |   |   |   |   |
| informatics by increasing the numbers   |   |   |    |   |   |   |   |   |
| of informatics-trained graduates in     |   |   |    |   |   |   |   |   |
| basic biomedical sciences, clinical     |   |   |    |   |   |   |   |   |
| medicine, and public health.            |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| *CBRR-6: By 2010, build capacity to     |   | X |    | X |   |   |   |   |
| conduct research by constructing or     |   |   |    |   |   |   |   |   |
| renovating extramural facilities to     |   |   |    |   |   |   |   |   |
| meet the biomedical and behavioral      |   |   |    |   |   |   |   |   |
| research, research training or research |   |   |    |   |   |   |   |   |
| support needs.*                         |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| *CBRR-7: By 2010, utilize enhanced ARIS |   |   |    |   |   |   |   | X |
| database to more efficiently conduct    |   |   |    |   |   |   |   |   |
| portfolio analysis to invest in         |   |   |    |   |   |   |   |   |
| priority AIDS research.*                |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| *CBRR-8: By 2012, ensure that 100% of   |   |   |    |   |   |   |   | X |
| trainee appointment forms are processed |   |   |    |   |   |   |   |   |
| electronically, to enhance program      |   |   |    |   |   |   |   |   |
| management.*                            |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| *CBRR-9: By 2010, achieve average       |   |   |    |   |   |   |   | X |
| annual cost savings of managing         |   |   |    |   |   |   |   |   |
| construction grants by expanding the    |   |   |    |   |   |   |   |   |
| use of electronic project management    |   |   |    |   |   |   |   |   |
| tools that enhance oversight and 20     |   |   |    |   |   |   |   |   |
| year usage monitoring.*                 |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| **Strategic Management of Human Capital |   |   |    |   |   |   |   |   |
| (SMHC)**                                |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| SMHC-3: Improve the strategic           |   |   |    |   |   |   |   | X |
| management of NIH resources by          |   |   |    |   |   |   |   |   |
| developing a comprehensive human        |   |   |    |   |   |   |   |   |
| capital plan based on the Agency's      |   |   |    |   |   |   |   |   |
| programmatic objectives and projected   |   |   |    |   |   |   |   |   |
| future needs.                           |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| SMHC-4: Ensure that NIH commercial      |   |   |    |   |   |   |   | X |
| functions are performed as efficiently  |   |   |    |   |   |   |   |   |
| and cost-effectively as possible by     |   |   |    |   |   |   |   |   |
| conducting competitive sourcing reviews |   |   |    |   |   |   |   |   |
| on the required number of functions     |   |   |    |   |   |   |   |   |
| within the Agency's commercial          |   |   |    |   |   |   |   |   |
| inventory.                              |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| SMHC-5: Improve and monitor the use of  |   |   |    |   |   |   |   | X |
| human resource services by providing    |   |   |    |   |   |   |   |   |
| real-time access to tools via the NIH   |   |   |    |   |   |   |   |   |
| Portal.                                 |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| **Program Oversight and Improvement     |   |   |    |   |   |   |   |   |
| (POI)**                                 |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| POI-1: By 2007, ensure that approved    |   |   |    |   |   |   |   | X |
| design and construction projects are    |   |   |    |   |   |   |   |   |
| executed on time, on scope, and on      |   |   |    |   |   |   |   |   |
| budget by implementing an Earned Value  |   |   |    |   |   |   |   |   |
| Analysis and Management System (EVAMS). |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| POI-2: Expand the use of                |   |   |    |   |   |   |   | X |
| Performance-Based Contracting (PBC).    |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| POI-5: By 2010, enhance NIH's ability   |   |   |    |   |   |   |   | X |
| to demonstrate benefits for extramural  |   |   |    |   |   |   |   |   |
| research investments through changes to |   |   |    |   |   |   |   |   |
| policy and information systems.         |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| POI-6: Provide responsible stewardship  |   |   |    |   |   |   |   | X |
| over existing federally owned real      |   |   |    |   |   |   |   |   |
| property assets.                        |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| POI-7: Manage design and construction   |   |   |    |   |   |   |   | X |
| of capital facility projects funded by  |   |   |    |   |   |   |   |   |
| the building and facilities             |   |   |    |   |   |   |   |   |
| appropriation (B&F) so the HHS and      |   |   |    |   |   |   |   |   |
| congressionally approved scope of work  |   |   |    |   |   |   |   |   |
| is delivered within the appropriate     |   |   |    |   |   |   |   |   |
| budget.                                 |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| POI-8: By 2010, protect NIH\'s interest |   |   |    |   |   |   |   | X |
| in real property supported under the    |   |   |    |   |   |   |   |   |
| extramural construction grant program   |   |   |    |   |   |   |   |   |
| by ensuring compliance with             |   |   |    |   |   |   |   |   |
| construction and 20 year usage          |   |   |    |   |   |   |   |   |
| requirements                            |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+
| *POI-9: By 2012, reallocation of        |   |   |    |   |   |   |   | X |
| laboratory resources based on external  |   |   |    |   |   |   |   |   |
| reviews by Boards of Scientific         |   |   |    |   |   |   |   |   |
| Counselors*                             |   |   |    |   |   |   |   |   |
+-----------------------------------------+---+---+----+---+---+---+---+---+